Catamaran Bio
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. The company's proprietary capabilities enable it to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.
Sector
Biopharmaceuticals
Strategies
Status
Live
Website
catamaranbio.com
Related News
Catamaran Bio to present preclinical data at ASGCT Annual Meeting to support CAR-NK approach for solid tumors
Catamaran Bio appoints Cherry Thomas, MD, as Chief Medical Officer
Catamaran Bio appoints Frank Lee as Chair of its Board of Directors
Catamaran Bio expands collaboration for CAR-NK cell engineering with the University of Minnesota and secures an exclusive patent license to next generation manufacturing technologies
Catamaran Bio announces appointment of Michael DeRidder, PhD, as senior vice president, corporate strategy and new product planning
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.